Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial

About this item

Title

Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial

Content partner

University of Otago

Collection

Otago University Research Archive

Description

We investigated whether 18 months of androgen suppression plus radiotherapy, with or without 18 months of zoledronic acid, is more effective than 6 months of neoadjuvant androgen suppression plus radiotherapy with or without zoledronic acid. We did an open-label, randomised, 2 × 2 factorial trial in men with locally advanced prostate cancer (either T2a N0 M0 prostatic adenocarcinomas with prostate-specific antigen [PSA] ≥10 μg/L and a Gleason score of ≥7, or T2b-4 N0 M0 tumours regardless of ...

Read more

Format

Research paper

Research format

Scholarly text / Journal article

Thesis level

Article

Date created

2014-09-01

Creator

Denham, James W / Joseph, David / Lamb, David S / Spry, Nigel A / Duchesne, Gillian / Matthews, John / Atkinson, Chris / Tai, Keen-Hun / Christie, David / Kenny, Lizbeth / Turner, Sandra / Gogna, Nirdosh Kumar / Diamond, Terry / Delahunt, Brett / Oldmeadow, Christopher / Attia, John / Steigler, Allison

URL

https://hdl.handle.net/10523/32053

Related subjects

Adenocarcinoma - mortality / Adenocarcinoma - pathology / Adenocarcinoma - therapy / Aged / Androgen Antagonists - therapeutic use / Antineoplastic Agents, Hormonal - therapeutic use / Brachytherapy - methods / Combined Modality Therapy / Diphosphonates - therapeutic use / Disease-Free Survival / Drug Administration Schedule / Follow-Up Studies / Humans / Imidazoles - therapeutic use / Male / Middle Aged / Neoplasm Invasiveness - pathology / Neoplasm Recurrence, Local - epidemiology / Neoplasm Recurrence, Local - pathology / Neoplasm Staging / Prostate-Specific Antigen - blood / Prostatic Neoplasms - mortality / Prostatic Neoplasms - pathology / Prostatic Neoplasms - therapy / Survival Analysis / Treatment Outcome

What is the copyright status of this item?

All Rights Reserved

This item is all rights reserved, which means you'll have to get permission from University of Otago before using it.

What can I do with this item?

You must always check with University of Otago to confirm the specific terms of use, but this is our understanding:

Non-infringing use

NZ Copyright law does not prevent every use of a copyright work. You should consider what you can and cannot do with a copyright work.

No sharing

You may not copy and/or share this item with others without further permission. This includes posting it on your blog, using it in a presentation, or any other public use.

No modifying

You are not allowed to adapt or remix this item into any other works.

No commercial use

You may not use this item commercially.